DOTA-ECL1i

Customer Review

Based on 1 Customer Validation

DOTA-ECL1i is a conjugate of the CCR2 inhibitor ECL1i (HY-P11553) and DOTA. When radiolabeled with 68Ga, DOTA-ECL1i serves as a PET tracer that targets CCR2 expression. DOTA-ECL1i can be used in research related to pulmonary fibrosis, cardiac injury, abdominal aortic aneurysm inflammation, atherosclerosis, head and neck cancer, and pancreatic cancer.

For research use only. We do not sell to patients.

  • Purity: 98.06%
  • CAS No.: 2850189-48-7
  • Formula: C58H94N14O18S
  • Molecular Weight:1307.51
  • Storage:

    Sealed storage, away from moisture.

    Powder   -80°C, 2 years , -20°C, 1 year

    * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Purity & Documentation
  • References
  • Help & FAQs

All Radionuclide-Drug Conjugates (RDCs) Isoforms

More
100 mg

Get Quote In-stock

Please select quantity
Amount: USD 0.00